Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study)
about
Management of Ewing sarcoma family of tumors: Current scenario and unmet needSurgical treatment of sarcomas of the spine.Ethnic and racial differences in patients with Ewing sarcoma.A Comparison of Pediatric vs. Adult Patients with the Ewing Sarcoma Family of TumorsEwing's Sarcoma Family Tumors in the Jaws: Case Report, Immunohistochemical Analysis and Literature Review.Treatment of nonmetastatic Ewing's sarcoma family tumors of the spine and sacrum: the experience from a single institution.Chemotherapy in Ewing's sarcoma.Comparison of Latino and non-Latino patients with Ewing sarcoma.Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection.Axial Skeletal Location Predicts Poor Outcome in Ewing's Sarcoma: A Single Institution Experience.Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomasTreatment of Bone TumorsRenal primitive neuroectodermal tumor: does age at diagnosis impact outcomes?The clinical use of biomarkers as prognostic factors in Ewing sarcoma.Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing: A Children's Oncology Group Report.Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy.Ewing sarcoma: clinical state-of-the-art.Some general considerations about the clinicopathologic aspects of soft tissue tumors in children and adolescents.Ethnicity and age disparities in Ewing sarcoma outcome.Diagnosis and prognosis for the Ewing family of tumors.Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Abnormal body mass index at diagnosis in patients with Ewing sarcoma is associated with inferior tumor necrosis.Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998.Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group.Treatment outcomes of Japanese patients with Ewing sarcoma: differences between skeletal and extraskeletal Ewing sarcoma.Role of radiation in the treatment of non-metastatic osseous Ewing sarcoma.Tandem high-dose chemotherapy strategy as first-line treatment of primary disseminated multifocal Ewing sarcomas in children, adolescents and young adults.Dramatic response to Cisplatin window therapy in a boy with advanced metastatic ewing sarcomaBone sarcomas: from biology to targeted therapies.High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk ewing sarcoma patients: a long-term follow-up single-center study.Is time of the essence? Delayed diagnosis of Ewing's sarcoma.The Scandinavian Sarcoma Group: 30 years' experience.2-Methoxyestradiol induces apoptosis in Ewing sarcoma cells through mitochondrial hydrogen peroxide production.Initial FDG-PET/CT predicts survival in adults Ewing sarcoma family of tumors.Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study.Primary non-metastatic Ewing sarcoma of the jaw in children: results of surgical resection and primary reconstruction.Efficacy Comparison of Six Chemotherapeutic Combinations for Osteosarcoma and Ewing's Sarcoma Treatment: A Network Meta-Analysis.Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma.Survival outcome among patients with Ewing's sarcoma of bones and joints: a population-based cohort study.
P2860
Q28073218-8D3FD4E1-2032-4ABA-8C85-BD2196DF04EBQ33275229-88687327-3F99-4AB3-8D41-B180D6CC5E45Q33643417-01BFBA95-40AB-448D-B31A-9602A697B4F2Q33646555-CCD74170-27D3-4F82-96FD-918969C2F840Q33770830-F848CE72-56B2-46E5-AFC1-F0E18A228C58Q33972685-37D3CCAD-9DDF-41B8-9C43-91CDEE309890Q34164686-DC468727-812D-4A06-B0E5-161E9C2C302BQ34387256-658C0EBB-9690-4BDB-8511-9907B51587D8Q35607070-8A9C5D6C-7F9B-49D6-A0A9-56DC2DE58ADFQ35608783-DAE53A5D-E2E1-406B-A676-AAB4DA77A0BCQ35683306-8E5BB7BB-8F5E-456F-82F6-8ADE4E356557Q35740708-4E8B852B-CFD2-4B3C-BCB6-831014D1E123Q35887373-A7E984BC-A5A4-4EF1-97CA-C085F2687622Q35957979-ED0CC533-7CF8-49D1-8BDC-DF096EDD46A6Q36174379-8A8E83F7-434B-41AF-828D-A556BC38EF94Q36907188-098DBD07-8D96-445F-8FFC-CFB95888A426Q37116507-F42F9C80-838B-4A94-8FA2-7F0CBA22AA3AQ37980482-E59CBC14-6420-4307-9157-12FFB779B722Q37989189-5E12664D-EC18-40F3-B554-F7F3446378F6Q38050170-97AF62C2-D41A-4790-8668-1F5870701397Q38088856-172EF8D0-C0DB-4E28-9A15-FF209E746F77Q38113988-0B8C5197-99C8-4FCE-92D9-BD34A478741AQ38520250-33F079E2-3CB9-4A9D-B858-6551D3E71D3EQ40318247-F673A5A6-AD73-413B-92BC-4EF0D6970E1CQ40702959-AE123FBD-B44C-43C3-9149-163EABD785A1Q40836328-3D0AE8C2-2F2C-4708-AD21-C73DA86EBBAFQ41258979-4326458A-62EC-4C28-805D-FE13FD40FEE0Q41704209-04D4062E-8B2A-4B73-A00F-04AAAA4BC8EDQ41881517-1AA88D02-BCAB-4389-98DB-BAA1F8ED9C11Q41923624-F6688862-9E88-438B-B5F5-1CEF49D37592Q43082436-2B37C484-CE4C-414D-9123-D6FF73A24E0AQ43139988-855455CA-0FC1-4D5C-AC8D-37657F90B8D7Q43589203-1AAC1082-5E04-4AF6-90F1-E0AA0752D13BQ44429627-8911DA0F-C26E-455B-9649-EB9A6DB5DE90Q47119469-5D77C69D-8373-43F6-A641-7466BFA0C29BQ47358394-D782F282-6002-4E88-9292-3E999AB0D023Q48072418-9FCE0317-8D54-44EA-A95B-F15FD28A69E7Q48156801-74D6FE37-333E-4C67-A8F5-F412DD6BAD11Q48239404-7A6CE5AF-7604-4CD6-9BDF-B326044DDD31Q48363948-3F883359-6951-4D56-BB6B-167DE0B7F056
P2860
Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study)
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Prognostic factors in localize ...... ediatric Oncology (EW88 study)
@ast
Prognostic factors in localize ...... ediatric Oncology (EW88 study)
@en
Prognostic factors in localize ...... ediatric Oncology (EW88 study)
@nl
type
label
Prognostic factors in localize ...... ediatric Oncology (EW88 study)
@ast
Prognostic factors in localize ...... ediatric Oncology (EW88 study)
@en
Prognostic factors in localize ...... ediatric Oncology (EW88 study)
@nl
prefLabel
Prognostic factors in localize ...... ediatric Oncology (EW88 study)
@ast
Prognostic factors in localize ...... ediatric Oncology (EW88 study)
@en
Prognostic factors in localize ...... ediatric Oncology (EW88 study)
@nl
P2093
P2860
P3181
P356
P1476
Prognostic factors in localize ...... ediatric Oncology (EW88 study)
@en
P2093
A Babin-Boillettot
F Mechinaud
J C Gentet
P2860
P2888
P304
P3181
P356
10.1054/BJOC.2001.2150
P407
P577
2001-11-30T00:00:00Z
P5875
P6179
1008994269